News from orexo A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages

Latest

08 Nov, 2019, 12:18 GMT Orexo to Present at Jefferies 2019 Healthcare Conference

Orexo AB (publ), the fully integrated specialty pharmaceutical company addressing opioid addiction and pain, today announces that the company will...


24 Oct, 2019, 07:46 BST Orexo Interim Report Q3 2019

Strong financials paving the way for broadening the business UPPSALA, Sweden, Oct. 24, 2019 Q3 2019 highlights Total net revenues of SEK 231.2...


14 Oct, 2019, 17:03 BST Orexo´s Nomination Committee for the Annual General Meeting 2020

Prior to the Annual General Meeting (AGM) in 2020, Orexo has appointed a Nomination Committee which represents approximately 44 percent of the number ...


20 Aug, 2019, 07:10 BST Orexo Signs Partnership Agreement With GAIA to Develop and Commercialize a new Digital Therapy for the Treatment of Opioid Use Disorder

Orexo AB (publ), the fully integrated specialty pharmaceutical company addressing opioid addiction and pain, today announces it has entered into an...


11 Jul, 2019, 07:40 BST Orexo Interim Report Q2 2019

Q2 2019 highlights Total net revenues of SEK 201.2 million (199.7), up 0.8 percent and 19.1 percent when excluding ex-US milestone payment of SEK...


10 Jul, 2019, 07:16 BST Orexo Signs License and Supply Agreement With Mundipharma for Zubsolv® in Australia and New Zealand

Orexo AB (publ.), the fully integrated specialty pharmaceutical company addressing opioid addiction and pain, today announces the company has signed...


09 Jul, 2019, 17:05 BST Orexo Prepays Part of the Corporate Bond Loan

rexo AB (publ.) has resolved to prepay SEK 32.5 million, corresponding to 10 percent, of the unsecured corporate bond loan of in total SEK 325...


28 Jun, 2019, 16:40 BST Number of Shares and Votes in Orexo

The number of shares and votes in Orexo AB (publ.) has changed as a result of the issue and repurchase of 63,000 class C shares as announced on June...


12 Jun, 2019, 16:41 BST Issue and Repurchase of Class C Shares

Orexo AB (publ.) announces that the company has resolved to issue and immediately thereafter repurchase 63,000 class C shares. The shares are issued...


31 May, 2019, 16:44 BST Number of Shares and Votes in Orexo

The number of votes in Orexo AB has changed as a result of the conversion of 110,029 class C shares into ordinary shares due to vesting under the...


17 May, 2019, 14:15 BST Orexo's Closest Upcoming Presentations at Conferences

Orexo AB (publ.), the fully integrated specialty pharmaceutical company addressing opioid addiction and pain, today announces that the company will...


02 May, 2019, 07:27 BST Orexo: Interim Report Q1 2019

Q1 2019 highlights Total net revenues of SEK 174.3 million (139.7), up 24.8 percent Zubsolv® US net revenues of SEK 161.7 million (131.1), up 23.3...


26 Apr, 2019, 16:44 BST Issues of Shares Following the Vesting of 2016/2019 Incentive Plan

The 2016 annual general meeting of Orexo resolved on a long-term incentive plan for senior executives and key employees within the Orexo group ("LTIP ...


11 Apr, 2019, 18:02 BST Report from Orexo AB's Annual General Meeting

Election of the board of directors and auditor The annual general meeting in Orexo AB (publ) on 11 April 2019 resolved, in accordance with the...


29 Mar, 2019, 15:29 GMT District Court of Delaware Rules that Actavis does not Infringe with their Suboxone® and Subutex® Generics

Orexo AB (publ.), the fully integrated specialty pharmaceutical company, with strong long-term patent protection (no. 8,940,330) for its key product, ...


21 Mar, 2019, 09:44 GMT Orexo Publishes the Annual Report for 2018

Orexo's Annual Report, including the Sustainability Report, for the 2018 fiscal year has been published and can be downloaded on the company's...


05 Mar, 2019, 17:34 GMT Notice of Annual General Meeting of Orexo

The shareholders in Orexo AB (publ), reg. no. 556500-0600, registered office Uppsala, are summoned to the annual general meeting, to be held on...


28 Feb, 2019, 17:13 GMT Number of Shares and Votes in Orexo

The number of shares and votes in Orexo AB has changed as a result of the exercise of warrants in connection with the company's incentive programs....


30 Jan, 2019, 07:28 GMT Q4 Incl. Full Year Report 2018

Q4 2018 highlights Total net revenues of SEK 227.1 million (191.0), up 18.9 percent from Q4 previous year Zubsolv® US net revenue of SEK 166.7...


11 Jan, 2019, 07:16 GMT Actavis Infringes Orexo's Long Term Zubsolv® U.S. Patent ´330

Orexo AB (publ.), the fully integrated specialty pharmaceutical company addressing opioid addiction and pain, today announces that the United States...


07 Jan, 2019, 07:18 GMT Positive Results From Human PK Study Assessing Orexo's New Intranasal Naloxone Formulations for Opioid Overdose Reversal

Orexo AB (publ), the fully integrated specialty pharmaceutical company addressing opioid addiction and pain, today announces positive results from...


13 Dec, 2018, 06:10 GMT Orexo Regains Rights to Zubsolv® in all Countries Outside the US

Orexo AB (publ.), the fully integrated specialty pharmaceutical company addressing opioid addiction and pain, today announces that the Company will...


06 Dec, 2018, 06:46 GMT Orexo Hosts Capital Markets Day Today in Stockholm, Sweden

Orexo AB (publ.), the fully integrated specialty pharmaceutical company addressing opioid addiction and pain, is today hosting the Company's Capital...


30 Nov, 2018, 07:18 GMT US Court of Appeals Denies Actavis's Petition for Rehearing Regarding Validity of the Zubsolv® Patent

Orexo AB (publ.) today announces that the US Court of Appeals for the Federal Circuit has denied Actavis Elizabeth LLC's (Actavis) combined petition...


08 Nov, 2018, 12:48 GMT Orexo to Host a Capital Markets Day on Dec. 6 With the US President´s Former Advisor as Keynote Speaker

rexo AB (publ.), the fully integrated specialty pharmaceutical company addressing opioid addiction and pain, invites investors, analysts and media to ...